The compound which is a DNA minor groove binder is currently in pre-clinical development with IND filing targeted for the third quarter of 2012.
Almac Operations VP Rick Dyer said with their expertise in early phase clinical development, the company is happy to take up this phase of work for MGB Biopharma.
The Almac Group is known for providing services in R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRStechnology (IVRS/IWRS), besides commercial-scale manufacture.